HTA-Ready Evidence Dossiers HTA (Health Technology Assessment)-ready evidence dossiers represent a critical deliverable for HEOR teams seeking market access and reimbursement for new therapies. These documents compile clinical, economic, and real-world evidence to meet strict requirements from health technology assessment bodies such as NICE, CADTH, or HAS. HTA-ready evidence dossiers demand more data, tighter timelines,…

AI in Evidence Generation was the quiet headline at ISPOR 2026 in Philadelphia this May. Most exhibit-hall chatter, though, was still about which chatbot gives the "smartest" answer. MadeAi presented four posters at ISPOR 2026. They covered literature review methodology, GenAI validation, drug repurposing, and social media listening for CSL Behring. Together, they tell a…

Why Evidence for Rare Disease Matters AI and real-world evidence (RWE) are reshaping the path from laboratory discovery to regulatory approval. Their convergence matters most for patients who can't afford to wait. For patients with rare diseases, waiting for treatment can mean years of uncertainty. In the United States, a rare disease is generally defined…